Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Financing Activities: 2014-2024

Historic Cash from Financing Activities for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $612.5 million.

  • Viking Therapeutics' Cash from Financing Activities fell 80.97% to $480,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 99.62%. This contributed to the annual value of $612.5 million for FY2024, which is 125.69% up from last year.
  • As of FY2024, Viking Therapeutics' Cash from Financing Activities stood at $612.5 million, which was up 125.69% from $271.4 million recorded in FY2023.
  • In the past 5 years, Viking Therapeutics' Cash from Financing Activities ranged from a high of $612.5 million in FY2024 and a low of $950,000 during FY2020.
  • Its 3-year average for Cash from Financing Activities is $296.0 million, with a median of $271.4 million in 2023.
  • As far as peak fluctuations go, Viking Therapeutics' Cash from Financing Activities tumbled by 39.49% in 2022, and later skyrocketed by 6,418.76% in 2023.
  • Over the past 5 years, Viking Therapeutics' Cash from Financing Activities (Yearly) stood at $950,000 in 2020, then soared by 624.21% to $6.9 million in 2021, then slumped by 39.49% to $4.2 million in 2022, then soared by 6,418.76% to $271.4 million in 2023, then spiked by 125.69% to $612.5 million in 2024.